Conducted by the University of Cincinnati, this study aims to determine if sirolimus can improve clinical outcomes for patients with a severe case of COVID-19, particularly those simultaneously experiencing pneumonia.

For each trial, thirty patients will be separated into three groups. With a 2:1 ratio, two groups will be given a 6mg of sirolimus on day one and 2mg of sirolimus on the next thirteen days or until hospital discharge (whichever comes first). The third group will be given placebo dosages. Observations will be recorded daily and specific biomarkers will be studied on day one, day three, day seven, and day fourteen.